Table 4.
Semaphorin involvment in diverse cancers. The very recent finding that SEMA3B inhibits tumor growth but fosters a prometastatic environment [95] adds complexity in the classification of SEMA3B as a pro- or anti-tumor semaphorin. exp., experiments
| SEMA | human tumor | in vitro exp. | in vivo exp. | effect | reference | |
|---|---|---|---|---|---|---|
| pro-tumoral | 3A | x | ≠tumor cell lines | x | inhibits the immune response | 135 |
| pancreas | x | x | correlates with shorter survival | 136 | ||
| 3B | glioblastoma | x | x | co-marker of poorer survival | 137 | |
| 3C | x | ovarian cancer cells | x | ovarian cancer drug resistance | 138 | |
| ovary | x | x | correlates with shorter survival | 139 | ||
| x | prostate cancer cells | x | invasive cellular growth | 140 | ||
| x | lung cancer cells | x | overexpression in metastatic cells | 109 | ||
| 3E | breast | breast cancer cells | breast cancer cells | pro-metastatic | 17,141 | |
| 4B | x | lung cancer cells | x | pro-migratory | 57 | |
| 4D | leukemia | x | x | pro-proliferative | 142 | |
| x | leukemia cells | x | anti-apoptotic | 143 | ||
| head and neck | h. and n. cancer cells | h. and n. cancer cells | pro-angiogenic | 13,77 | ||
| x | breast cancer cells | x | invasive growth and pro-migratory | 144 | ||
| 5A | prostate | x | x | correlates with aggressiveness | 121 | |
| 5B | kidney | x | x | increased expression in tumors | 145 | |
| 5c | x | x | drosophila model | pro-metastatic | 146 | |
| 6A | kidney | renal cancer cells | renal cancer cells | correlates with tumor vascularization | 78 | |
| 6D | stomach | x | x | increased expression in tumors | 147 | |
| anti-tumoral | 3A | x | breast cancer cells | x | anti-migratory | 148 |
| x | mesothelioma cells | x | negative retrocontrol of VEGF | 149 | ||
| myeloma | myeloma cells | x | negative retrocontrol | 104 | ||
| x | prostate cancer cells | x | anti-invasive in vitro | 140 | ||
| 3B | lung | x | x | gene deleted in tumors | 5 | |
| x | lung cancer cells | x | in vitro tumoral suppression | 87 | ||
| x | lung cancer cells | x | lower expression in metastatic cells | 90 | ||
| lung | x | x | lower expression in tumors | 86 | ||
| x | lung cancer cells | x | pro-apoptotic | 89 | ||
| x | ovarian cancer cells | ovarian cancer cells | in vivo tumoral suppression | 88 | ||
| 3F | lung | x | x | gene deleted in tumors | 6,7 | |
| lung | ≠ cell lines | x | early expression loss | 85,98 | ||
| lung | x | x | lower expression in tumors | 85,98 | ||
| x | lung cancer cells | lung cancer cells | anti-angiogenic + tumoral suppression | 81,82,101 | ||
| x | melanoma cells | melanoma cells | anti-metastatic | 79 | ||
| x | HEK293 cells | HEK293 cells | anti-angiogenic | 80 | ||
| x | x | murine fibrosarcoma cells | in vivo tumoral suppression | 100 | ||
| x | breast cancer cells | x | anti-migratory | 102,103 | ||
| 4B | B-cell lymphoma | x | x | expression loss | 150 | |
| 4D | x | breast cancer cells | x | anti-migratory | 63 |